The most common kidney injury from chronic lithium ingestion is nephrogenic diabetes insipidus (NDI) due to lithium-induced resistance to ADH. Typically patients present with acute-onset nocturia, as well as polydipsia and polyuria. Approximately 20%-40% of patients taking lithium develop NDI. It is important to differentiate NDI from central diabetes insipidus and primary polydipsia, as these disorders also cause polydipsia and polyuria and can be seen in patients with psychiatric illness.
Lithium-induced NDI can be irreversible with chronic lithium use, so the best treatment is discontinuation of the drug. An alternative therapy for patients unable to discontinue lithium is amiloride, which minimizes accumulation of lithium into the collecting tubules where it interferes with the effects of ADH. This is not as effective in severe NDI. Other therapies include thiazide diuretics, NSAIDs, and desmopressin (DDAVP).
Chronic lithium use can also cause chronic kidney disease due to interstitial nephritis (15%-20% of patients) and less often renal tubular acidosis or nephrotic syndrome. The risk increases with duration of treatment and dose. It is rare for lithium to cause progression to end-stage renal disease, although this can occur.
N14.2 – Nephropathy induced by unspecified drug, medicament or biological substance
4390004 – Lithium nephropathy
- Hypertensive nephrosclerosis
- Analgesic nephropathy
- Renovascular disease (eg, renal artery stenosis)
- Diabetic nephropathy